The Treatment of Respiratory Pseudomonas Infection in Cystic Fibrosis: What Drug and Which Way?

Author： Banerjee D.   Stableforth D.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.60, Iss.5, 2000-11, pp. : 1053-1064

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review

By  

Drug Delivery Letters, Vol. 4, Iss. 3, 2014-12 ,pp. : 193-207

Bentham Science Publishers

Access to resources Recommend Favorite

Natalizumab for keeping patients out of HARRMS way?

By  

Inpharma, Vol. 1, Iss. 1644, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Natalizumab for keeping patients out of HARRMS way?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 557, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Recurrent Clostridium difficile Infection: What are the Treatment Options?

By >   Verbon Annelies   Kuipers Ernst J.  

Drugs, Vol. 71, Iss. 7, 2011-05 ,pp. : 853-868

Adis International

Access to resources Recommend Favorite

Drug-Resistant Tuberculosis: What are the Treatment Options?

By Albanna Amr S.   Menzies Dick  

Drugs, Vol. 71, Iss. 7, 2011-05 ,pp. : 815-825

Adis International

Access to resources Recommend Favorite